Brittle Asthma by Toungoussova, O et al.
Monaldi Arch Chest Dis
2007; 67: 2, 102-105 REVIEW
Brittle asthma
O. Toungoussova1, M.P. Foschino Barbaro2, L.M. Esposito1, 
G.E. Carpagnano2, F. G. Salerno1, R.W. Dal Negro3, A. Spanevello1,2
Asthma is characterised by chronic airway in-
flammation, variable airflow obstruction and air-
way hyper-responsiveness, accompanied by recur-
rent episodes of coughing, wheezing, breathless-
ness and chest tightness [1]. Airflow limitation is
usually relieved at least partially either sponta-
neously or by bronchodilators.
Over the years, different classifications of
asthma based on the evaluation of etiological fac-
tors, pathology, symptoms, clinical phenotypes
and severity of the disease were described [2-4].
The standard classification based on symptoms
and lung function defines the severity of asthma
(mild intermittent, mild persistent, moderate per-
sistent and severe persistent). Patients with the
same severity of asthma can be characterised by
different clinical phenotypes of the disease. Brittle
asthma is one of these phenotypes at the severe
end of the spectrum [5, 6]. Brittle asthma is also re-
ferred to in scientific literature as unstable or un-
predictable asthma [7]. Patients with brittle asthma
can have mild intermittent symptoms progressing
suddenly to severe, life threatening attacks, which
are difficult to control [5].
The present review aims to present updated
knowledge on brittle asthma, a particular pheno-
type of asthma disease, with a special emphasis on
definition, classification, mechanisms, risk factors,
clinical picture, diagnosis and management.
Definition
The term “brittle asthma” has been used since
1977, when it was introduced by Turner-Warwick to
describe patients with chaotic variations of peak ex-
piratory flow (PEF) leading to severe attacks of
asthma, which were difficult to control with usual
treatment [8]. Based on daily monitoring of PEF in
patients with sudden, severe, life threatening at-
tacks, the definition of brittle asthma was updated.
Brittle asthma was defined as a diurnal PEF vari-
ability of > 50% on at least three days per week de-
spite maximal medical treatment including high
doses of inhaled corticosteroids with repeated doses
of inhaled bronchodilator and maintenance or
courses of oral corticosteroids [9]. This definition
was more complete, however, it did not specify the
doses of corticosteroids and inhaled bronchodilator;
and it did not include sudden severe life threatening
attacks on the background of apparently good asth-
ma control. Later, the high doses of medical therapy
were specified, and two phenotypes of patients with
the severe disease were described [10, 11].
Type 1 brittle asthma is characterised by a main-
tained wide PEF variability (> 40% diurnal varia-
tion for > 50% of the time over a period of at least
150 days) despite considerable medical therapy in-
cluding a dose of inhaled steroids of at least 1500 µg
of beclomethasone or equivalent [11, 12, 13].
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Brittle asthma is a clinical phenotype of the disease at
the severe end of the spectrum. Type 1 brittle asthma is
characterised by a maintained wide PEF variability (> 40%
diurnal variation for > 50% of the time over a period of at
least 150 days) despite considerable medical therapy in-
cluding a dose of inhaled steroids of at least 1500 µg of be-
clomethasone or equivalent. Type 2 brittle asthma is char-
acterised by sudden acute attacks occurring in less than
three hours without an obvious trigger on a background of
apparent normal airway function or well controlled asth-
ma. Mechanisms behind the development of brittle asthma
include smooth muscle contraction and edema of the air-
ways, which are supported by chronic airway inflamma-
tion. Allergy reactions, impairment of local immunity, res-
piratory infections, psycho-social disorders and reduced
perception of worsening airway function are the risk factors
for brittle asthma. The diagnosis is based on the analysis of
specific symptoms, role of triggers, personal or family his-
tory, measurement of lung function and PEF monitoring.
Pharmacological treatment of type 1 brittle asthma in addi-
tion to the high doses of inhaled and/or oral steroids and
bronchodilators includes subcutaneous injections of β2 ago-
nist and inhalation of long acting β2 agonist. The treatment
of patients with type 2 brittle asthma includes exclusion of
allergen exposure, identification of triggers, self manage-
ment and management of acute attacks.
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Type 2 brittle asthma is characterised by sud-
den acute attacks occurring in less than three hours
without an obvious trigger on a background of ap-
parent normal airway function or well controlled
asthma [11, 12, 13] (table 1).
Mechanisms
Scientific reports published so far did not de-
scribe precisely the underlying mechanisms of
brittle asthma development. The lack of the
knowledge is mainly due to the high risk exposure
and development of severe attack during the diag-
nostic procedures. Measurements of lung function,
methacholine inhalation challenge and induction
of sputum in patients with brittle asthma can be
potentially dangerous since one forced expiratory
manoeuver can be enough to cause significant
worsening the of patient’s condition.
Mechanisms behind the development of severe
asthma have been studied thoroughly [2, 12, 14]. It
is possible, that pathological events observed in
brittle asthma may be similar to those occurring in
severe asthma. The mechanisms of the sudden se-
vere airway narrowing include smooth muscle
contraction and edema of the airways, which are
supported by chronic inflammation.
Smooth muscle contraction of airways is
rapidly induced by many allergens; it is activated
by a cholinergic reflex and by local release of
tachykinins, substance P, bronchoconstrictor and
inflammatory peptides [15]. Edema of the airways
occurs due to acute vasodilatation and plasma ex-
udation from post-capillary venules as a result of
anaphylactic reaction [15, 16]. The chronic in-
flammation involves infiltration of the airway wall
with different cells, mainly with eosinophils and
neutrophils. Elevated eosinophils can be con-
trolled by treatment with high doses of corticos-
teroids, while the count of neutrophils remain the
same resulting in an alteration of the repair
process, epithelial damage, extensive mucus plug
and abnormalities of epithelial and endothelial per-
meability [12, 14]. Persistence of airway infiltra-
tion with eosinophils and neutrophils leads to fixed
airflow obstruction or airway remodelling [1]. Air-
way remodelling is part of the structural alterations
including subepithelial collagen and matrix protein
disposition, smooth muscle cell hypertrophy, an-
giogenesis, and goblet cell metaplasia [17].
Risk factors
Mainly risk factors for type 1 brittle asthma
have been presented in scientific publications. The
risk factors for type 2 brittle asthma include only
exposure to aeroallergens such as fungal spores
and poor perception of the disease [12].
The majority of patients with type 1 brittle asth-
ma is atopic with the evidence of at least one posi-
tive skin prick test for cat, horse, wheat and choco-
late allergens. Positive reaction to Der-
matophagoides pteronyssinus is also possible; how-
ever, it is not specific for patients with brittle asth-
ma [12]. More than half (over 60%) of the patients
are allergic to dairy products, wheat, fish, citrus,
egg, potato, soya, peanut and yeast, which are the
most common food triggers for brittle asthma [11].
Low levels of circulating IgG and IgA suggest
an impairment of local immunity and increasing
susceptibility to respiratory infections [12]. Respi-
ratory tract infections can contribute to the severity
of asthma and precipitate acute severe exacerba-
tions [3, 7, 14]. There is some evidence to suggest
that Mycoplasma pneumoniae may be found in pa-
tients with more severe asthma and could act as a
perpetuating mechanism [18]. Persistant infection
with Chlamydia pneumoniae is also associated
with more frequent exacerbations of asthma and it
can be another infection that worsens asthma.
Table 1. - Comparison of type I and type II brittle asthma
Characteristics Type I brittle asthma Type II brittle asthma
Definition PEF variability (> 40% diurnal variation for Sudden acute attacks occurring in less than
> 50% of the time over a period of at least 150 days) 3 hours without an obvious trigger on a
background of apparent normal airway function
Risk factors • Atopy • Exposure to aeroallergens such as fungal spores
• Impairment of local immunity • Poor perception of the disease
• Increasing susceptibility to respiratory infections
• Psychosocial factors
Patients Women aged between 15 and 55 years Equally prevalent in men and women
Morbidity High –
Mortality – High
Treatment • Inhaled and/or oral steroids • Control of allergen exposure
• Inhaled bronchodilators • Identification of triggers
• Control of allergen exposure • Self management and management of acute 
• Immunotherapy attacks
• Insurance of patient’s compliance
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Psycho-social factors play an important role,
depressions, frequent evidence of broken relation-
ships and physical and sexual abuse are often in
patients with type 1 brittle asthma [11, 12, 16]. The
nature of psycho-social disorders remain unclear.
It is difficult to distinguish whether brittle asthma
is associated with personality disorder or whether
asthma itself induces psychological instability
[12].
Patients with the experience of severe attacks
of asthma have a reduced perception of worsening
airway function and reduced hypoxic drive, even
when the lung function is normal, suggesting that
during an acute attack they may not have a normal
ventilatory response and delay taking the appropri-
ate therapy [12, 19].
Clinical picture and diagnosis
Brittle asthma is recognised by sudden life
threatening attacks on the background of wide PEF
variability or apparent normal airway function and
significant difficulties to manage the disease [20].
The diagnosis is based on the analysis of specific
symptoms, role of triggers, personal or family his-
tory, measurement of lung function and PEF mon-
itoring [21].
Type 1 brittle asthma is characterised by se-
vere attack developed on the background of wide
PEF variability (> 40% diurnal variation for > 50%
of the time over a period of at least 150 days) de-
spite considerable medical therapy including a
dose of inhaled steroids of at least 1500 µg of be-
clomethasone or equivalent. PEF readings should
be corrected for non-linearity when calculating di-
urnal variation [10]. Type 1 brittle asthma is more
prevalent in women aged between 15 and 55 years
[17], who have reduced values of total lung capac-
ity and functional residual capacity at around 80%
predicted [22]. Patients are frequently admitted for
long hospital stays due to severe attacks and for as-
sessment, stabilisation and prescription medica-
tion. Treatment with the high doses of inhaled and
oral steroids leads to the development of glucose
intolerance, weight gain and obstructive sleep ap-
noea [16]. Oesophageal reflux observed in patients
with type 1 brittle asthma is a side effect of bron-
chodilators and increased negative intra-pleural
pressures [6].
Type 2 brittle asthma is equally prevalent in
men and women [16]. It is characterised by sudden
acute attacks occurring in less than three hours
without an obvious trigger on a background of ap-
parently normal airway function or well controlled
asthma. Hospital admissions are rare, erratic and
occur at unpredictable intervals when patients de-
velop sudden severe attacks of asthma. The attacks
often impose risk of death and often require venti-
lation [16].
Treatment of type 1 brittle asthma
Patients with type 1 brittle asthma already re-
ceive treatment with the high doses of inhaled
and/or oral steroids and inhaled bronchodilators,
thus, application of the standard guidelines for
asthma treatment is difficult [21]. Non-pharmaco-
logical treatment includes the control of allergen
exposure, identification and avoidance of allergic
food, good dietary support, immunotherapy and
insurance of patient’s compliance [5, 11].
The treatment begins with a control of allergen
exposure and avoidance of food products of which
the patients are intolerant [5]. Control of allergen
exposure is difficult since many patients show re-
sistance to exclude contact and exposure to ani-
mals.
Good dietary support is important for patients
who eat a very restricted diet aimed at avoiding
food allergens and controlling calorie intake. The
excessive weight gain usually results from treat-
ment with oral steroids. The diet of these patients
should be complemented with minerals and vita-
mins to substitute significant deficiency of vita-
mins A and E and low intake of magnesium, sele-
nium and vitamin C [23].
Scientific papers demonstrate that oral admin-
istration of immunomodulators like cyclosporine
and methotrexate [5] or intravenous immunoglob-
ulin [14] can relieve immunosuppression caused
by the high doses of steroids. However, current
guidelines do not recommend the use of aforemen-
tioned drugs for the treatment of asthma outside of
new control trials. Methotrexate may have a small
steroid sparing effect in adults with asthma who
are dependent on oral corticosteroids. However,
the overall reduction in daily steroid use is proba-
bly not large enough to reduce steroid-induced ad-
verse effects. This small potential to reduce the im-
pact of steroid side-effects is probably insufficient
to offset the adverse effects of methotrexate [24].
Given the side effects of cyclosporin, the evidence
available does not recommend routine use of this
drug in the treatment of oral corticosteroid depen-
dent asthma [25]. Current guidelines on use of in-
travenous immunoglobulin in human disease do
not recommend the use of intravenous im-
munoglobulins for the treatment of asthma outside
of new control trials [26].
Compliance with the treatment is a very impor-
tant issue, in particular when management is ex-
tremely difficult according to the definition. The rea-
sons for patients’ non-compliance include lack of
immediate benefit from anti-inflammatory therapy,
fears of side effects and failure to take the prescribed
treatment correctly [7, 27]. Patients with brittle asth-
ma often try management tricks to avoid having to
start or increase a dose of oral steroids [16].
Pharmacological treatment of type 1 brittle
asthma in addition to the high doses of inhaled
and/or oral steroids and bronchodilators includes
subcutaneous injections of β2 agonist and inhala-
tion of long acting β2 agonist.
Treatment with a long-term continuous subcu-
taneous infusion of β2 agonist terbutaline at doses
of 3-12 mg/day show significant improvement in
PEF variation in about 50% of patients, and im-
provement of symptoms and reduction of other
medications in 25% of patients [5, 16]. Develop-
ment of side effects including significant changes
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in serum potassium or glucose concentrations,
tremor, muscle cramps with elevation of plasma
creatinine phosphokinase, memory problems, abil-
ity to concentrate and occasional menorrhagia can
be avoided by maintenance of the therapeutical
range of terbutaline [11, 13]. Many patients devel-
op subcutaneous inflammatory nodules with
eosinophilic infiltrate during continuous subcuta-
neous infusions. These usually settle down once
that area of skin is avoided, but often leave a fi-
brotic nodule. In case of aggressive type of lesion,
the formation of a clinically evident abscess con-
taining sterile pus is observed [16].
Long acting inhaled β2 agonists (salmeterol
and formoterol) should be effective in type 1 brit-
tle asthma in view of the wide variation in PEF and
the success of terbutaline. However, salmetorol
has proved to be disappointing in these patients for
unknown reasons [16], while improvement of lung
function and reduction of symptoms were docu-
mented for formotorol [28].
Treatment of type 2 brittle asthma
The treatment of patients with type 2 brittle
asthma, that are relatively symptom free, includes
control of allergen exposure, identification of trig-
gers, self management and management of acute
attacks [14]. Every patient should be supplied with
a card providing relevant information because of
sudden, severe, unexpected attacks that require
emergent interventions.
The treatment of acute attacks includes imme-
diate administration of adrenalin in preloaded sy-
ringes and administration of a bronchodilator [7].
Adrenalin has theoretical advantages over selec-
tive β1 agonists, because of its action as an alpha
adrenoreceptor against reducing airway edema
[10]. Once adrenalin has been injected the patient
should be advised to use a dose of nebulised salbu-
tamol or terbutaline and proceed to causialty. In
the case of acute respiratory insufficiency, me-
chanical lung ventilation is required.
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